US · TCRT
Alaunos Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Houston, TX 77054
- Website
- alaunos.com
Price · as of 2024-12-31
$2.61
Market cap 7.12M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $585.17 | +22,320.31% |
| Intrinsic Value(DCF) | $0.65 | -75.1% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $876.00 | ||||
| 2011 | $738.00 | $3.93 | $0.00 | ||
| 2012 | $756.00 | $305.90 | $0.00 | $0.00 | $0.00 |
| 2013 | $636.00 | $416.49 | $0.00 | $0.00 | $0.00 |
| 2014 | $1,998.00 | $1,225.96 | $32.39 | $0.00 | $0.00 |
| 2015 | $1,272.00 | $1,652.60 | $46,206.48 | $0.00 | $0.00 |
| 2016 | $1,033.50 | $281,969.33 | $1,394.50 | $0.00 | $0.00 |
| 2017 | $651.00 | $277.97 | $0.11 | $0.00 | $0.00 |
| 2018 | $432.00 | $172.80 | $20.45 | $0.00 | $4,742.35 |
| 2019 | $487.50 | $195.00 | |||
| 2020 | $658.50 | ||||
| 2021 | $109.50 | $0.00 | $0.00 | ||
| 2022 | $76.50 | $285.18 | $3.45 | $0.00 | $0.00 |
| 2023 | $19.00 | $7.60 | $0.00 | $0.00 | $1,918.57 |
| 2024 | $1.62 | $585.17 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Alaunos Therapeutics, Inc.'s (TCRT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $585.17
- Current price
- $2.61
- AI upside
- +22,320.31%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.65
-75.1% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TCRT | Alaunos Therapeutics, Inc… | $2.61 | 7.12M | +22,320% | -75% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
| ADXN | Addex Therapeutics Ltd | $7.28 | 4.81M | +9,333% | +38% | +845% | — | 0.71 | 0.52 | 12.45 | -0.37 | — | 0.52 | 100.00% | -681.82% | 1746.04% | 130.39% | -137.95% | 92.11% | 0.00 | -776.78 | 4.42 | 4.19 | 0.71 | -15000.00% | -7495.00% | -3281.00% | -106.85% | -6.70 | -269.11% | 0.00% | 0.00% | 0.00% | -0.63 | -0.32 | 4.27 | -43.82 |
| CYCN | Cyclerion Therapeutics, I… | $1.35 | 5.14M | — | +2,196,706% | — | — | -2.31 | 0.80 | 3.53 | -1.05 | — | 0.80 | 100.00% | -181.40% | -152.85% | -30.36% | -77.73% | -26.64% | 0.00 | — | 5.83 | 5.22 | 0.89 | -8654.00% | — | -7960.00% | -61.46% | -5.98 | -92.83% | 0.00% | 0.00% | 0.00% | -1.05 | -0.88 | 1.91 | -33.88 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| PLRZ | Polyrizon Ltd. | $12.49 | 13.01M | — | — | — | — | -8.81 | 2.58 | — | -7.77 | — | 5.67 | 0.00% | — | — | -57.83% | -88.33% | -50.61% | 0.00 | -434.00 | 10.16 | 9.79 | 1.79 | — | — | 11359.00% | -8.43% | -4.39 | -77.82% | 0.00% | 0.00% | 20.20% | -8.49 | -9.64 | — | 29.76 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| RADX | Radiopharm Theranostics L… | $4.99 | 6.43M | +1,761% | — | — | — | — | 1.36 | 16.76 | -0.83 | — | -34.17 | 1.08% | -1050.63% | -1055.27% | 0.00% | -302.69% | 0.00% | 0.00 | -584.59 | 2.67 | 2.65 | 0.76 | -8533.00% | 111427.00% | 5950.00% | -60.17% | -2.45 | -290.58% | 0.00% | — | 17.31% | -0.83 | -0.87 | 8.75 | -2.59 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
| XTLB | XTL Biopharmaceuticals Lt… | $0.76 | 1.04M | — | +76% | — | — | -2.05 | 0.39 | 4.66 | -1.18 | — | -1.34 | 0.67% | -481.60% | -227.72% | -26.83% | -83.03% | -18.71% | 0.03 | -25.26 | 0.61 | 0.56 | 0.25 | — | — | 13649.00% | -79.50% | -0.73 | -72.01% | 0.00% | 0.00% | 0.00% | -0.51 | -0.66 | 2.44 | -26.54 |
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
- CEO
- Ferdinand Groenewald
- Employees
- 1
- Beta
- -1.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.65 ÷ $2.61) − 1 = -75.1% (DCF, example).